AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

ERS Genomics Provides Comment on Issuance of University of California CRISPR/Cas9 Patent Including Uses of CRISPR ‘in a cell’

March 12, 2019

DUBLIN--(BUSINESS WIRE)--Mar 12, 2019--ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a new patent to Dr. Emmanuelle Charpentier, together with The Regents of the University of California and University of Vienna (collectively, UC). U.S. Patent No. 10,227,611 specifically includes uses of single guide RNA formats of the CRISPR/Cas9 technology ‘in a cell’. In a cell specifically includes any cell type, including animal, plant and human cells. ERS Genomics is an exclusive licensee of certain rights in the UC patents from Dr. Charpentier.

Eric Rhodes, CEO of ERS Genomics, said: “We are pleased that the seminal contribution of Dr. Charpentier and her colleagues to CRISPR/Cas9 technology continues to be recognized by patent offices in the United States and around the world.”

UC already has two granted patents relating to CRISPR/Cas9 in the U.S., with a fourth expected to grant soon.

For additional information please visit www.ersgenomics.com

ENDS

Note to Editors

Eric Rhodes, CEO, ERS Genomics

For a high-resolution image please contact Zyme Communications

To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.com . To view our privacy policy please click her e .

About ERS Genomics www.ersgenomics.com

ERS Genomics is a biotechnology company based in Dublin, Ireland. The company was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; companion animal and livestock health; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. For additional information please visit www.ersgenomics.com

View source version on businesswire.com:https://www.businesswire.com/news/home/20190312005371/en/

CONTACT: Media contact:

Katie Odgaard

Zyme Communications

Tel: +44(0)7787 502 947

Email:katie.odgaard@zymecommunications.com

KEYWORD: EUROPE IRELAND

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS MEDICAL DEVICES PHARMACEUTICAL

SOURCE: ERS Genomics Limited

Copyright Business Wire 2019.

PUB: 03/12/2019 05:08 AM/DISC: 03/12/2019 05:08 AM

http://www.businesswire.com/news/home/20190312005371/en